Come up with a name for your new list and we'll add to it:
Impact Biomedicines was acquired by
Celgene on January 08, 2018.
Impact Biomedicines is developing treatments for patients with complex cancers. The company's pipeline is centered around fedratinib, a potent and highly selective oral small molecule JAK2 kinase inhi…